Yu C, Gershwin ME, Chang C (2014) Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 48-49:10–13. https://doi.org/10.1016/j.jaut.2014.01.004
Article
CAS
PubMed
Google Scholar
Mok CC, Kwok RC, Yip PS (2013) Effect of renal disease on the standardized mortality ratio and life expectancy of patients with systemic lupus erythematosus. Arthritis Rheum 65(8):2154–2160. https://doi.org/10.1002/art.38006
Article
CAS
PubMed
Google Scholar
Borchers AT, Leibushor N, Naguwa SM, Cheema GS, Shoenfeld Y, Gershwin ME (2012) Lupus nephritis: a critical review. Autoimmun Rev 12(2):174–194. https://doi.org/10.1016/j.autrev.2012.08.018
Article
PubMed
Google Scholar
Austin HA 3rd, Klippel JH, Balow JE, le Riche NG, Steinberg AD, Plotz PH, Decker JL (1986) Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 314(10):614–619. https://doi.org/10.1056/NEJM198603063141004
Article
PubMed
Google Scholar
Contreras G, Pardo V, Leclercq B, Lenz O, Tozman E, O’Nan P, Roth D (2004) Sequential therapies for proliferative lupus nephritis. N Engl J Med 350(10):971–980. https://doi.org/10.1056/NEJMoa031855
Article
CAS
PubMed
Google Scholar
Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon GE, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gul A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R (2010) The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69(1):61–64. https://doi.org/10.1136/ard.2008.102533
Article
CAS
PubMed
Google Scholar
Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, Lau CS, Wong AK, Tong MK, Chan KW, Lai KN (2000) Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. Engl J Med 343(16):1156–1162. https://doi.org/10.1056/NEJM200010193431604
Article
CAS
Google Scholar
Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li LS, Mysler E, Sanchez-Guerrero J, Solomons N, Wofsy D, Aspreva Lupus Management Study G (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20(5):1103–1112. https://doi.org/10.1681/ASN.2008101028
Article
CAS
PubMed
PubMed Central
Google Scholar
Rovin BH (2009) Glomerular disease: lupus nephritis treatment: are we beyond cyclophosphamide? Nat Rev Nephrol 5(9):492–494. https://doi.org/10.1038/nrneph.2009.130
Article
CAS
PubMed
Google Scholar
Hahn BH, McMahon MA, Wilkinson A, Wallace WD, Daikh DI, Fitzgerald JD, Karpouzas GA, Merrill JT, Wallace DJ, Yazdany J, Ramsey-Goldman R, Singh K, Khalighi M, Choi SI, Gogia M, Kafaja S, Kamgar M, Lau C, Martin WJ, Parikh S, Peng J, Rastogi A, Chen W, Grossman JM, American College of R (2012) American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis. Arthritis Care Res 64(6):797–808. https://doi.org/10.1002/acr.21664
Article
Google Scholar
Radhakrishnan J, Cattran DC (2012) The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines--application to the individual patient. Kidney Int 82(8):840–856. https://doi.org/10.1038/ki.2012.280
Article
PubMed
Google Scholar
Davis JM 3rd, Matteson EL, American College of R, European League Against R (2012) My treatment approach to rheumatoid arthritis. Mayo Clin Proc 87(7):659–673. https://doi.org/10.1016/j.mayocp.2012.03.011
Article
CAS
PubMed
PubMed Central
Google Scholar
Behrens F, Koehm M, Burkhardt H (2011) Update 2011: leflunomide in rheumatoid arthritis - strengths and weaknesses. Curr Opin Rheumatol 23(3):282–287. https://doi.org/10.1097/BOR.0b013e328344fddb
Article
CAS
PubMed
Google Scholar
Breedveld FC, Dayer JM (2000) Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 59(11):841–849
Article
CAS
PubMed
PubMed Central
Google Scholar
Fragoso YD, Brooks JB (2015) Leflunomide and teriflunomide: altering the metabolism of pyrimidines for the treatment of autoimmune diseases. Expert Rev Clin Pharmacol 8(3):315–320. https://doi.org/10.1586/17512433.2015.1019343
Article
CAS
PubMed
Google Scholar
Remer CF, Weisman MH, Wallace DJ (2001) Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 10(7):480–483. https://doi.org/10.1191/096120301678416033
Article
CAS
PubMed
Google Scholar
Tam LS, Li EK, Wong CK, Lam CW, Szeto CC (2004) Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 13(8):601–604. https://doi.org/10.1191/0961203304lu1067sr
Article
CAS
PubMed
Google Scholar
Yang S, Xie L, Xue W, Yin A, Lu W (2013) Leflunomide plus oral prednisone in treatment of idiopathic membranous nephropathy: a retrospective clinical study of efficacy and safety. Nephrology 18(9):615–622. https://doi.org/10.1111/nep.12143
Article
CAS
PubMed
Google Scholar
Lou T, Wang C, Chen Z, Shi C, Tang H, Liu X, Yin P, Yu X (2006) Randomised controlled trial of leflunomide in the treatment of immunoglobulin A nephropathy. Nephrology 11(2):113–116. https://doi.org/10.1111/j.1440-1797.2006.00547.x
Article
CAS
PubMed
Google Scholar
Wang HY, Cui TG, Hou FF, Ni ZH, Chen XM, Lu FM, Xu FF, Yu XQ, Zhang FS, Zhao XZ, Zhao MH, Wang GB, Qian JQ, Cai GY, Zhu TY, Wang YH, Jiang ZP, Li YN, Mei CL, Zou WZ, China Leflunomide Lupus Nephritis Study G (2008) Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 17(7):638–644. https://doi.org/10.1177/0961203308089408
Article
CAS
PubMed
Google Scholar
Tam LS, Li EK, Wong CK, Lam CW, Li WC, Szeto CC (2006) Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open label trial. Ann Rheum Dis 65(3):417–418. https://doi.org/10.1136/ard.2005.044248
Article
PubMed
PubMed Central
Google Scholar
Cao H, Rao Y, Liu L, Lin J, Yang H, Zhang X, Chen Z (2015) The efficacy and safety of leflunomide for the treatment of lupus nephritis in Chinese patients: systematic review and meta-analysis. PLoS One 10(12):e0144548. https://doi.org/10.1371/journal.pone.0144548
Article
PubMed
PubMed Central
Google Scholar
Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40(9):1725. https://doi.org/10.1002/1529-0131(199709)40:9<1725::AID-ART29>3.0.CO;2-Y
Article
CAS
PubMed
Google Scholar
Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi LM, Makino H, Moura LA, Nagata M, International Society of Nephrology Working Group on the Classification of Lupus N, Renal Pathology Society Working Group on the Classification of Lupus N (2004) The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65(2):521–530. https://doi.org/10.1111/j.1523-1755.2004.00443.x
Article
PubMed
Google Scholar
Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TT, Balow JE (1984) Diffuse proliferative lupus nephritis: identification of specific pathologic features affecting renal outcome. Kidney Int 25(4):689–695
Article
PubMed
Google Scholar
Wiacek R, Kolossa K, Jankowski T, Jeka S, Karmowski A, Karmowski M, Gworys B (2012) The efficacy and safety of leflunomide in patients with active rheumatoid arthritis. Adv Clin Exp Med 21(3):337–342
PubMed
Google Scholar
Xu X, Blinder L, Shen J, Gong H, Finnegan A, Williams JW, Chong AS (1997) In vivo mechanism by which leflunomide controls lymphoproliferative and autoimmune disease in MRL/MpJ-lpr/lpr mice. J Immunol 159(1):167–174
CAS
PubMed
Google Scholar
He C, Lu X, Yan Z, Wu M, Liu S, Yu Y, Luo P (2012) Therapeutic effect of leflunomide on the development of experimental lupus nephritis in mice. Rheumatol Int 32(3):633–638. https://doi.org/10.1007/s00296-010-1630-z
Article
CAS
PubMed
Google Scholar